Pfizer inks new GKA development deal with China's Pegbio
HONG KONG – Pfizer Inc. (NYSE:PFE) will partner with Suzhou-based Pegbio Co. Ltd. to develop glucokinase activator (GKA) drugs for China as part of the multinational's strategy of using local partners to further the development of innovative drugs that address unmet needs in China.
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST